26886, a novel carnitine acyltransferase family member and uses therefor
OwnerRachel A. Meyers, Mark Williamsoninventors
Life of this patent
Estimating the term…
Abstract
The invention provides isolated nucleic acids molecules, designated 26886 nucleic acid molecules, which encode a novel carnitine acyltransferase. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 26886 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 26886 gene has been introduced or disrupted. The invention still further provides isolated 26886 proteins, fusion proteins, antigenic peptides and anti-26886 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
Claims41
An isolated nucleic acid molecule selected from the group consisting of:
- a) a nucleic acid molecule comprising a nucleotide sequence of SEQ ID NO:1, 3, or the cDNA insert of the plasmid deposited with the ATCC as Accession Number ______;
- b) a nucleic acid molecule comprising a fragment of at least 300 nucleotides of the nucleotide sequence of SEQ ID NO:1, 3, or the cDNA insert of the plasmid deposited with the ATCC as Accession Number ______;
- c) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC as Accession Number ______;
- d) a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC as Accession Number ______, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:2, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC as Accession Number ______;
- and
- e) a nucleic acid molecule which encodes a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC as Accession Number ______, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID NO:1, 3, or a complement thereof, under stringent conditions.
An isolated polypeptide selected from the group consisting of:
- a) a polypeptide which is encoded by a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1, 3, the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC as Accession Number ______, or a complement thereof.
- b) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC as Accession Number ______, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes under highly stringent conditions to a nucleic acid molecule comprising SEQ ID NO:1, 3, or a complement thereof under highly stringent conditions;
- and
- c) a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC as Accession Number ______, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:2.
A method for evaluating the efficacy of a treatment of a proliferative disorder, in a subject, comprising:
- treating a subject with a protocol under evaluation;
- evaluating the expression of a 26886 nucleic acid or polypeptide,
- wherein a change in the level of 26886 nucleic acid or polypeptide after treatment, relative to the level of expression before treatment, is indicative of the efficacy of the treatment of the disorder.
Dependencies are inferred from the claim text.